HS
Hamsa Sandhya Rani
About Hamsa Sandhya Rani
Data last updated:
Hamsa Sandhya Rani is a Director at Innovative Pharma Solutions Private Limited (since 2024) and Director at V3s Life Sciences Private Limited (since 2023). The companies operate in Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹3.03 Cr; the largest is Innovative Pharma Solutions Private Limited at ₹2.63 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 30 Dec 2024 | 2019 | ₹2.63 Cr (FY 2024) | Active | |
| Director | 23 Mar 2023 | 2023 | ₹40.2 Lakh (FY 2024) | Active |
Board colleagues of Hamsa Sandhya Rani
| Name | DIN | Company | Designation |
|---|---|---|---|
| Vijaya Kumar Hamsa | 10085720 | Innovative Pharma Solutions Private Limited , V3s Life Sciences Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Hamsa Sandhya Rani
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hamsa Sandhya Rani
Hamsa Sandhya Rani currently holds 2 directorships: Innovative Pharma Solutions Private Limited (Director, since 30 Dec 2024, revenue ₹2.63 Cr (FY 2024)); V3s Life Sciences Private Limited (Director, since 23 Mar 2023, revenue ₹40.2 Lakh (FY 2024)).
Hamsa Sandhya Rani was first appointed on 23 Mar 2023 as Director at V3s Life Sciences Private Limited. The most recent appointment on record is 30 Dec 2024 at Innovative Pharma Solutions Private Limited.
The 2 current companies of Hamsa Sandhya Rani that report revenue have a combined latest revenue of ₹3.03 Cr: Innovative Pharma Solutions Private Limited ₹2.63 Cr (FY 2024); V3s Life Sciences Private Limited ₹40.2 Lakh (FY 2024).
The current boards of Hamsa Sandhya Rani's companies include Vijaya Kumar Hamsa (Innovative Pharma Solutions Private Limited).